About HitGen
HitGen is a publicly listed company based in Lanzhou (China) founded in 2012. DNA-encoded libraries are developed for drug discovery applications. It operates on a Professional Services and SaaS (Software-as-a-Service) model. HitGen has raised $39.11 million across 2 funding rounds from investors including Gates Foundation, CDH and Shiyu Capital. The company has 483 employees. HitGen has completed 1 acquisition, including Vernalis. Its chief executive, as recorded, is Jin Li. HitGen offers products and services including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD). Its focus areas include Biotechnology and Drug Discovery. Its legal entity is HitGen Inc.
Company details
HitGen Inc. is involved in drug discovery research, focusing on the development of novel medicines and agrochemicals. The company is headquartered in Chengdu, China, with operations in the UK and USA. Advanced technology platforms such as DNA-encoded library (DEL), fragment-based drug discovery (FBDDSBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD) are utilized. Collaboration with numerous biopharmaceutical organizations worldwide is maintained, supporting projects from early discovery to clinical trials. A DELAIAutomated DMTA platform is being developed to enhance preclinical candidate optimization. Diverse sectors including healthcare and agriculture are served through flexible business models.
- Headquarters Lanzhou, China
- Employees 483
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website hitgen.com/en
- Social LinkedIn X Facebook
- Legal Name Hitgen Inc. Class A
- Annual Revenue$75.07 M (USD)23.09as on Dec 31, 2025
- Net Profit$15.64 M (USD)113.22as on Dec 31, 2025
- EBITDA$23.84 M (USD)43.13as on Dec 31, 2025
- Total Equity Funding$39.11M (USD)
in 2 rounds
- InvestorsGates Foundation
& 2 more
- Employee Count483
- Investments & Acquisitions
Products & Services of HitGen
HitGen offers a comprehensive portfolio of products and services, including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).
Technology used for designing and screening compound libraries.
Methods applied for structure-based drug design optimization.
Platform developed for nucleic acid drug discovery.
Technology utilized for protein degradation drug development.
Funding Insights of HitGen
HitGen has successfully raised a total of $39.11M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.11M
- Total Rounds 2
- First Round $39.11M
(May 2018)
- Investors Count 3
All 2 funding rounds of HitGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in HitGen
HitGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, CDH and Shiyu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
Shiyu Capital is engaged in equity investment and asset allocation. | shiyucapital.com | Beijing, China | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for HitGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HitGen
22 people are tracked at HitGen (15 in leadership, 7 in team); the tracked headcount is 483.
| Name | Role | Group |
|---|---|---|
Jin Li | CEO & President | Leadership |
Guansai Liu | Senior Vice President And Head Of Discovery Chemistry Unit | Leadership |
Shimiao (Felix） Yu | Director Of Business Development | Leadership |
barry morgan | Chief Scientific Officer | Leadership |
Dou Dengfeng | Vice President, Lead Generation Unit | Leadership |
Alex Shaginian, PhD, MBA | Vice President of Business Development and Chemical Sciences | Leadership |
Huiyong Ma | Director | Leadership |
Fangchao Liu | Associate Director Of DEL Screening And Assay | Leadership |
Su Yahui | Vice President of Clinical Development | Leadership |
Greg Bial | Director Of Business Development | Leadership |
Jing Chen | Executive Director, Biology | Leadership |
Xiaoyu Tian | Director of Strategic Alliances | Leadership |
Shaojie Wang | Director of Business Support Department | Leadership |
Sherman LIU | Senior Director of BD | Leadership |
Xuemin Cheng | Senior Director Of Computational Science | Leadership |
Zhenhuan Shi | IP Manager | Team |
Yuan Zhang | Business Development Manager | Team |
思丽 周 | Senior Project Manager | Team |
Muralikrishna Katta, Ph.D | Scientist | Team |
Qian Lin | Senior Scientist | Team |
2 more people are available in the full profile.
Complete people profiles for HitGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HitGen
HitGen is a publicly listed company on the SSE with ticker symbol 688222 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Apr 2020
- Listed onSSE: 688222
- Listed entityHitgen Inc. Class A
- Exchange sectorHealth technology
- ISINCNE1000040G3
- Share price37.01 CNY (-3.52% on the day) · 2026-10-14
- Market capitalisation15,388,986,148.00 CNY
- Price to earnings105.7
- EPS (diluted, trailing year)0.35 CNY
- Dividend yield0.34%
- Volume (last session)12,319,215
Financials of HitGen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 525.6M CNY | 109.5M CNY | 166.9M CNY |
| 2024 | 427.0M CNY | 51.4M CNY | 116.6M CNY |
| 2023 | 367.5M CNY | 40.7M CNY | 60.1M CNY |
| 2022 | 329.5M CNY | 25.3M CNY | 30.6M CNY |
| 2021 | 310.9M CNY | 63.4M CNY | 47.9M CNY |
Detailed financial statements for HitGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HitGen
HitGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vernalis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vernalis is engaged in structure-based drug discovery collaborations. | vernalis.com | Wokingham, United Kingdom | 1999 | Oct 2020 | $25M |
Complete acquisition details for HitGen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of HitGen
5 dated milestones of HitGen across 8 years, from founding to its latest funding, stage changes and deals.
- Founded HitGen is founded.
- Funding First funding round of $39.1M.
- Funding Latest funding round, Grant,.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Vernalis.
Web traffic of HitGen
The website of HitGen (hitgen.com) receives about 8.7K visits a month and ranks #2,210,392 among all websites worldwide, #3,010 in Biotechnology and Pharmaceuticals.
- Monthly visits8.7K
▼ 27.9% vs previous month
- Unique visitors6.2K
per month
- Global rank#2,210,392
among all websites
- Category rank#3,010
Health · Biotechnology and Pharmaceuticals
- Bounce rate68%
- Pages per visit1.2
- Average visit45 sec
- DevicesDesktop 11% · Mobile 89%
Websites whose visitors overlap most with HitGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vbdata.cn | 100% | 103.3K | #249,158 | View details | |
| immunocure.us | 59% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hitgen
Complete news archive for HitGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HitGen
HitGen was founded in 2012 and raised its 1st funding round 6 years after it was founded.
HitGen is headquartered in Lanzhou, China. It is registered at Lanzhou, Gansu, China.
Jin Li is the CEO of HitGen, as recorded in our data.
HitGen is a funded company, having raised a total of $39.11M across 2 funding rounds to date. The company's 1st funding round was a Series B of $39.11M, raised on May 2018.
HitGen has 483 employees.
Annual revenue of HitGen is $75.07M as on Dec 31, 2025.
HitGen Inc. is involved in drug discovery research, focusing on the development of novel medicines and agrochemicals. The company is headquartered in Chengdu, China, with operations in the UK and USA. Advanced technology platforms such as DNA-encoded library (DEL), fragment-based drug discovery (FBDDSBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD) are utilized. Collaboration with numerous biopharmaceutical organizations worldwide is maintained, supporting projects from early discovery to clinical trials. A DELAIAutomated DMTA platform is being developed to enhance preclinical candidate optimization. Diverse sectors including healthcare and agriculture are served through flexible business models.
HitGen offers DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).
Yes, HitGen is publicly traded on SSE under the ticker symbol 688222.
HitGen has made 1 acquisition, including Vernalis.
HitGen has 3 investors. Key investors include Gates Foundation, CDH, and Shiyu Capital.
HitGen operates through Hitgen Inc..